Close Menu

    Subscribe to Updates

    Get the latest creative news from FooBar about art, design and business.

    What's Hot

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    International Ombudsman Forum Establishes Worldwide Independent Defender Union (WIDU)

    November 19, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026
    Oran Star: Algeria’s news. Maghreb perspective.Oran Star: Algeria’s news. Maghreb perspective.
    • Automotive
    • Business
    • Entertainment
    • Health
    • Lifestyle
    • Luxury
    • News
    • Sports
    • Technology
    • Travel
    Oran Star: Algeria’s news. Maghreb perspective.Oran Star: Algeria’s news. Maghreb perspective.
    Home » Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot
    ACCESS Newswire

    Ad Scientiam Launches International Study to Assess Disability Progression in Multiple Sclerosis With MSCopilot

    September 12, 2023
    Facebook WhatsApp Twitter Pinterest LinkedIn Telegram Tumblr Email Reddit VKontakte

    PARIS, FRANCE / ACCESSWIRE / September 12, 2023 / Ad Scientiam, a global leader in digital biomarkers, has announced a partnership with Sanofi to launch MS-DETECT, an international, multicenter, longitudinal study. MS-DETECT aims to evaluate the ability of MSCopilot®, a medical software device, to detect early signs of disability worsening in people with multiple sclerosis (PwMS). The study will draw upon Ad Scientiam’s expertise in MS and is financially supported by Sanofi.

    AdS logo
    AdS logo

    Multiple Sclerosis (MS) is a chronic immune-mediated disease of the central nervous system that affects 2.8 million people worldwide. The disease is characterized by early inflammatory demyelination and subsequent neurodegeneration. Current clinical evaluation of PwMS relies mainly on the Expanded Disability Status Scale (EDSS), which has several limitations. To improve on these assessments, Ad Scientiam has developed MSCopilot®, a software medical device that addresses four dimensions: ambulation/mobility, upper extremity function, cognition, and low-contrast visual acuity.

    MS-DETECT’s main objective is to determine MSCopilot®’s ability to identify subtle and early disability worsening. This will be performed by evaluating MSCopilot® individual and/or composite scores as compared to the Multiple Sclerosis Functional Composite (MSFC) and the EDSS.

    “MS-DETECT is a pioneering large-scale longitudinal study that explores digital biomarkers for the early detection of disease progression. This study will provide important data to both clinicians and people living with MS,” according to Dr. Saad Zinaï, Chief Medical Officer at Ad Scientiam.

    “Disability worsening in MS has been recently redefined and we now know that this progression can occur independently of relapses. With MS-DETECT, we have an opportunity to develop a digital solution to help detect and monitor the effects of smoldering disease, and evolve treatment goals for MS patients,” explains Su-Peing Ng, Global Head of Medical Affairs – Specialty Care at Sanofi.

    The study also aims to assess the MSCopilot® performance, safety, usability and satisfaction with the solution.

    “Disease progression can be hard to detect in routine practice. I believe these novel digital biomarkers are key to help clinicians make appropriate treatment decisions and, ultimately, improve patients’ care,” said Prof. Patrick Vermersch (Lille, France), Coordinating Investigator and Chairman of the Study Steering Committee.

    The MS-DETECT study will include 314 PwMS and will be conducted in the United States, Canada, Germany, Italy, Spain, Denmark and France. Several investigative sites have already been initiated in North America and Europe and first patients are expected to participate in the study during Q3 2023.

    Check our LinkedIn, Facebook, Instagram pages or visit adscientiam.com

    Contact Information

    Saad Zinaï
    Chief Medical Officer
    szinai@adscientiam.com
    +33768008666

    Matthieu Lamy
    President
    mlamy@adscientiam.com
    +33768008666

    SOURCE: Ad Scientiam

    View source version on accesswire.com:
    https://www.accesswire.com/782728/ad-scientiam-launches-international-study-to-assess-disability-progression-in-multiple-sclerosis-with-mscopilot

    Related Posts

    Freezz Italia Awarded ESA Contract for IRIS(2) Low-LEO Pre-Operational and De-Risk Activities

    November 17, 2026

    Miami Fashion Week(R) Celebrates 10 Years With a Landmark Anniversary Edition, October 13-18, 2026

    October 26, 2026

    Ostathi, Operated by UniHouse, Pioneers the Middle East’s First Digital Infrastructure Linking Structured Workforce Development to Verified Income

    May 7, 2026

    ZOQQ Approaches Breakeven on a Bootstrapped Path – Bucking the Burn-First Fintech Playbook

    May 4, 2026

    Datavault AI Further Expands IP Portfolio with New Patent Issuance and Notices of Allowance

    April 22, 2026

    Datavault AI Announces Upcoming Listing of Meme Coin Portfolio and Institutional RWA Token Suite on the Biconomy Exchange

    April 13, 2026
    Current News

    Air Arabia Egypt launches Cairo to Al Ain flights now

    November 20, 2026

    Botswana opens consultations on proposed 33 percent hike now

    November 19, 2026

    PM Modi meets Prince and Princess of Wales in New Delhi

    November 19, 2026

    Rand slips toward R17 as inflation and weak growth cloud outlook

    November 18, 2026

    Congo Ebola death toll reaches 5,568 as cases pass 11,000

    November 18, 2026

    Prabowo says DEFA can unlock $2 trillion ASEAN digital economy

    November 18, 2026

    DXB handles 50.4 million passengers in first nine months

    November 18, 2026

    Tunisia tourism revenues top $2.38 billion by end-October

    November 17, 2026
    © 2026 Oran Star | All Rights Reserved
    • Home
    • Contact Us

    Type above and press Enter to search. Press Esc to cancel.